Lysosomally cleavable peptide-containing polymersomes modified with anti-EGFR antibody for systemic cancer chemotherapy

Biomaterials

Volumn 32, Issue 34, 2011, Pages 9144-9153

  Lee, Jung S ^a   Groothuis, Tom ^a   Cusan, Claudia ^b   Mink, Daniel ^b   Feijen, Jan ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b DSM Pharmaceutical Products   (Netherlands)

Author keywords

Anti epidermal growth factor receptor antibody; Biodegradable polymersomes; Cathepsin B; Chemotherapy; Peptide conjugated block copolymer

Indexed keywords

ACRIDINE ORANGE; ALEXA FLUOR; ANTI-EGFR; AVERAGE DIAMETER; BIODEGRADABLE POLYMERSOMES; CANCER CHEMOTHERAPY; CATHEPSIN B; CELLULAR UPTAKE; ENZYMATIC DEGRADATION; FLUORESCEIN ISOTHIOCYANATE; FUNCTION OF TIME; GROWTH FACTOR; MEMBRANE DISRUPTION; MEMBRANE THICKNESS; METHOXY POLY(ETHYLENE GLYCOL); MODEL DRUGS; NEGATIVE CONTROL; NO BINDING; PEPTIDE LINKERS; POLY(D ,L-LACTIDE); POLYMERSOMES; RAPID RELEASE; SPECIFIC BINDING;

ANTIBODIES; BIODEGRADABLE POLYMERS; BLOCK COPOLYMERS; CATALYST ACTIVITY; CELLS; CHEMOTHERAPY; DEGRADATION; DISPERSIONS; DYNAMIC LIGHT SCATTERING; ETHYLENE; GLYCOLS; MAMMALS; MOTION PICTURE EXPERTS GROUP STANDARDS; ORGANIC POLYMERS; POLYETHYLENE GLYCOLS; TRANSMISSION ELECTRON MICROSCOPY;

PEPTIDES;

ACRIDINE ORANGE; CATHEPSIN B; COPOLYMER; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; METHOXYPOLY(ETHYLENE GLYCOL)GLYCYLPHENYLALANYLLEUCYLGLYCYLPHENYLALANINE POLY(DEXTRO LEVO LACTIDE)BLOCK COPOLYMER; POLYMERSOME; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PH; POLYMER PRODUCTION; PRECIPITATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; TRANSMISSION ELECTRON MICROSCOPY;

ACRIDINE ORANGE; ANTIBODIES, IMMOBILIZED; CATHEPSIN B; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LYSOSOMES; NEOPLASMS; PEPTIDES; POLYESTERS; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

ALEXA; CAPRA HIRCUS;

EID: 80053104154     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.036     Document Type: Article

References (43)

1. Antonietti M., Forster S. Vesicles and liposomes: a self-assembly principle beyond lipids. Adv Mater 2003, 15:1323-1333.
2. Meng F.H., Zhong Z.Y., Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:197-209.
3. Chen W., Meng F.H., Cheng R., Zhong Z.Y. pH-sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 2010, 142:40-46.
4. Qin S.H., Geng Y., Discher D.E., Yang S. Temperature-controlled assembly and release from polymer vesicles of poly(ethylene oxide)-block-poly(N-isopropylacrylamide). Adv Mater 2006, 18:2905-2909.
5. Napoli A., Boerakker M.J., Tirelli N., Nolte R.J.M., Sommerdijk N.A.J.M., Hubbell J.A. Glucose-oxidase based self-destructing polymeric vesicles. Langmuir 2004, 20:3487-3491.
6. Elliott E., Sloane B.F. The cysteine protease cathepsin B in cancer. Perspect Drug Discov Design 1996, 6:12-32.
7. Sloane B.F., Yan S.Q., Podgorski I., Linebaugh B.E., Cher M.L., Mai J.X., et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol 2005, 15:149-157.
8. Yan S.Q., Sameni M., Sloane B.F. Cathepsin B and human tumor progression. Biol Chem 1998, 379:113-123.
9. Hruby M., Etrych T., Kucka J., Forsterova M., Ulbrich K. Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue. J Appl Polym Sci 2006, 101:3192-3201.
10. Pechar M., Ulbrich K., Jelinkova M., Rihova B. Conjugates of antibody-targeted PEG multiblock polymers with doxorubicin in cancer therapy. Macromol Biosci 2003, 3:364-372.
11. Satchi R., Connors T.A., Duncan R. PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br J Cancer 2001, 85:1070-1076.
12. Satchi-Fainaro R., Hailu H., Davies J.W., Summerford C., Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem 2003, 14:797-804.
13. Satchi R., Duncan R. PDEPT: polymer directed enzyme prodrug therapy - in vitro and in vivo characterisation. Ann Oncol 1998, 9:83.
14. Satchi R., Duncan R. PDEPT: polymer-directed enzyme prodrug therapy. Br J Cancer 1998, 78:149-150.
15. Kopecek J., Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62:122-149.
16. Ahmed F., Photos P.J., Discher D.E. Polymersomes as viral capsid mimics. Drug Dev Res 2006, 67:4-14.
17. Bermudez H., Brannan A.K., Hammer D.A., Bates F.S., Discher D.E. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules 2002, 35:8203-8208.
18. Discher D.E., Eisenberg A. Polymer vesicles. Science 2002, 297:967-973.
19. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003, 90:323-334.
20. Discher B.M., Hammer D.A., Bates F.S., Discher D.E. Polymer vesicles in various media. Curr Opin Colloid Interface Sci 2000, 5:125-131.
21. VertutDoi A., Ishiwata H., Miyajima K. Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Biochim Biophys Acta-Biomembr 1996, 1278:19-28.
22. Soga O., van Nostrum C.F., Fens M., Rijcken C.J.F., Schiffelers R.M., Storm G., et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005, 103:341-353.
23. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors - a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
24. Noh T., Kook Y.H., Park C., Youn H., Kim H., Oh E.T., et al. Block copolymer micelles conjugated with anti-EGFR antibody for targeted delivery of anticancer drug. J Polym Sci Pol Chem 2008, 46:7321-7331.
25. Mitchell A.R., Kent S.B.H., Engelhard M., Merrifield R.B. New synthetic route to tert-butyloxycarbonylaminoacyl-4-(oxymethyl)phenylacetamidomethyl-resin, an improved support for solid-phase peptide-synthesis. J Org Chem 1978, 43:2845-2852.
26. Wang S.S., Merrifie Rb Solid phase-fragment approach to peptide synthesis - application of a t-alkyloxycarbonylhydrazide resin and a t-alkyl alcohol resin. Int J Pept Protein Res 1972, 4:309-318.
27. Meng F.H., Engbers G.H.M., Feijen J. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. J Control Release 2005, 101:187-198.
28. Pechar M., Strohalm J., Ulbrich K., Schacht E. Biodegradable drug carriers based on poly(ethylene glycol) block copolymers. Macromol Chem Phys 1997, 198:1009-1020.
29. Rejmanova P., Kopecek J., Pohl J., Baudys M., Kostka V. Polymers containing enzymatically degradable bonds. 8. degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide co-polymers by bovine spleen cathepsin-B. Macromol Chem Phys 1983, 184:2009-2020.
30. Pata V., Ahmed F., Discher D.E., Dan N. Membrane solubilization by detergent: resistance conferred by thickness. Langmuir 2004, 20:3888-3893.
31. Lee J.S., Zhou W., Meng F.H., Zhang D.W., Otto C., Feijen J. Thermosensitive hydrogel-containing polymersomes for controlled drug delivery. J Control Release 2010, 146:400-408.
32. Lee J.C.M., Bermudez H., Discher B.M., Sheehan M.A., Won Y.Y., Bates F.S., et al. Preparation, stability, and in vitro performance of vesicles made with diblock copolymers. Biotechnol Bioeng 2001, 73:135-145.
33. Nardin C., Hirt T., Leukel J., Meier W. Polymerized ABA triblock copolymer vesicles. Langmuir 2000, 16:1035-1041.
34. 2O. Macromolecules 2000, 33:2561-2572.
35. Frosch B.A., Berquin I., Emmert-Buck M.R., Moin K., Sloane B.F. Molecular regulation, membrane association and secretion of tumor cathepsin B. Apmis 1999, 107:28-37.
36. Linke M., Herzog V., Brix K. Trafficking of lysosomal cathepsin B-green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment. J Cell Sci 2002, 115:4877-4889.
37. Giusti I., D'Ascenzo S., Millimaggi D., Taraboletti G., Carta G., Franceschini N., et al. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008, 10:481-488.
38. vanderStappen J.W.J., Williams A.C., Maciewicz R.A., Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996, 67:547-554.
39. Zhao G.M., Zhou G.H., Wang Y.L., Xu X.L., Huan Y.J., Wu J.Q. Time-related changes in cathepsin B and L activities during processing of Jinhua ham as a function of pH, salt and temperature. Meat Sci 2005, 70:381-388.
40. Clerc S., Barenholz Y. A quantitative model for using acridine orange as a transmembrane pH gradient probe. Anal Biochem 1998, 259:104-111.
41. Palmgren M.G. Acridine-orange as a probe for measuring pH gradients across membranes - mechanism and limitations. Anal Biochem 1991, 192:316-321.
42. Maruyama K., Takizawa T., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev 1997, 24:235-242.
43. Ahmed F., Pakunlu R.I., Brannan A., Bates F., Minko T., Discher D.E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 2006, 116:150-158.